Document is current
Any future updates will be listed below
-
Authors
Glaviano, Antonino
Lau, Hannah Si-Hui
Carter, Lukas M.
Lee, E. Hui Clarissa
Lam, Hiu Yan
Okina, Elena
Tan, Donavan Jia Jie
Tan, Wency
Ang, Hui Li
Carbone, Daniela
Yee, Michelle Yi-Hui
Shanmugam, Muthu K.
Huang, Xiao Zi
Sethi, Gautam
Tan, Tuan Zea
Lim, Lina H. K.
Huang, Ruby Yun-Ju
Ungefroren, Hendrik
Giovannetti, Elisa
Tang, Dean G.
Bruno, Tullia C.
Luo, Peng
Andersen, Mads Hald
Qian, Bin-Zhi
Ishihara, Jun
Radisky, Derek C.
Elias, Salem
Yadav, Saurabh
Kim, Minah
Robert, Caroline
Diana, Patrizia
Schalper, Kurt A.
Shi, Tao
Merghoub, Taha
Krebs, Simone
Kusumbe, Anjali P.
Davids, Matthew S.
Brown, Jennifer R.
Kumar, Alan Prem
-
Funding
Funding for this research was provided by:
Ministry of Education - Singapore (MOE-T2EP30120-0016)
National University Health System (NUHSRO/2023/039/RO5+6/Seed-Mar/04)
- License Information
-
More Information
Article History
Received: 20 April 2024
Accepted: 11 November 2024
First Online: 13 January 2025
Declarations
:
: Not Applicable.
: We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all the authors. All figures are original and were drawn using BioRender by the authors for this review.
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work in this paper. M.H.A. is founder, shareholder and scientific advisor of IO Biotech ApS. LMC is a consultant for Evergreen Theragnostics. S.K. has consulted for Telix Pharmaceuticals Ltd., acknowledges support for investigator services from RayzeBio and holds the following patent: PCT/US2021/039418 (THOR cell (tumor homing radio-emitting cell).
